LEO Pharma's PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition read more
Positive Results for LEO Pharma's Phase III Actinic Keratosis Trials on the Face and Scalp read more
Letter to our CDI Holders read more
Current report
Archived